| Name | Title | Contact Details |
|---|
InsightRX is a healthcare technology company that has developed a platform for precision medicine and clinical analytics designed to individualize treatment at the point of care.
IMAC Regeneration Centers offers long-term solutions for chronic musculoskeletal conditions without surgery or opioids. This state-of-the-art medical treatment utilizes a combination of regenerative medicine and rehabilitation to prevent the most common unnecessary surgeries, including spinal fusion and laminectomy, and knee and hip replacements. Each of these surgeries require an opioid prescription 99.9% of the time, leading to a high risk of addiction and never returning to work.
Tower Health is a regional integrated healthcare system that offers leading-edge, compassionate healthcare and wellness services to communities in Berks, Chester, Montgomery, and Philadelphia Counties. With nearly 12,000 team members, Tower Health consists of Reading Hospital in West Reading; Chestnut Hill Hospital in Philadelphia; Phoenixville Hospital in Phoenixville; Pottstown Hospital in Pottstown; and St. Christopher`s Hospital for Children, a partnership of Tower Health and Drexel University in Philadelphia. It also includes Reading Hospital Rehabilitation at Wyomissing; Reading Hospital School of Health Sciences in West Reading; home healthcare provided by Tower Health at Home; TowerDirect ambulance and emergency response; Tower Health Medical Group; and a network of 25 urgent care facilities across the Tower Health service area.
JBN Scientifica Inc is a Mendham, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Our efforts are currently focused on the fields of neurology, nephrology and rheumatology, areas of medicine which have significant unmet medical needs. Our main product is H.P Acthar® Gel (repository corticotropin injection), a naturally-derived formulation of adrenocorticotropic hormones used in a variety of disorders having an inflammatory component. We are currently supporting research in a number of rare conditions, where there is significant unmet need for treatment alternatives to standard therapies. We are also actively supporting research efforts to better understand disease processes and therapeutic mechanisms of action in conditions where Acthar might potentially play a role in treatment.